Renal disease in hypertensive adults: effect of race and type II diabetes mellitus
- PMID: 2729268
- DOI: 10.1016/s0272-6386(89)80006-x
Renal disease in hypertensive adults: effect of race and type II diabetes mellitus
Abstract
To test the hypothesis that race is a predictor of hypertensive renal disease, we examined a general medicine clinic population of 6,880 hypertensive patients who were treated for at least 1 year (mean, 5.2 years). Their mean age was 55.8 years; 70% were women, 72% were black, and 41% were diabetic (95% type II). Many were already under treatment at the time of enrollment. Their mean blood pressure at entry was 150/92 mmHg; during treatment it was 142/86 mmHg. Decreased renal function, defined as a serum creatinine greater than or equal to 2 mg/dL, developed in 18.1%. A multivariable logistic regression analysis identified diabetes, glucose control, systolic blood pressure levels, heart failure, and male gender as indicators of decreased renal function. These data suggested that glucose and blood pressure control may decrease the frequency of impaired renal function. However, when these variables were controlled, blacks still had almost twice the risk for renal dysfunction (91% greater risk) than whites (P less than 0.0001). With increasing creatinine values, the percentage of black patients increased progressively. The data draw attention to and elucidate the exceptionally high incidence of renal dysfunction in blacks with or without diabetes. Further, they may explain the inordinate numbers of blacks with hypertension requiring dialysis. Finally, these retrospective data suggest that prospective trials to test the effect of blood pressure and glucose control on the course of renal disease in hypertensive and/or type II diabetic patients are warranted.
Similar articles
-
Effect of hypertension and type II diabetes on renal function in an urban population.Am J Hypertens. 1990 Jan;3(1):69-75. doi: 10.1093/ajh/3.1.69. Am J Hypertens. 1990. PMID: 2302332
-
Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study.Am J Kidney Dis. 1993 Apr;21(4 Suppl 1):31-40. doi: 10.1016/s0272-6386(12)80859-6. Am J Kidney Dis. 1993. PMID: 8465834 Clinical Trial.
-
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group.JAMA. 1992 Dec 2;268(21):3085-91. JAMA. 1992. PMID: 1433739 Clinical Trial.
-
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.J Hypertens. 2017 May;35(5):922-944. doi: 10.1097/HJH.0000000000001276. J Hypertens. 2017. PMID: 28141660 Review.
-
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.
Cited by
-
Temporal trends in hypertension related end stage renal disease mortality rates: an analysis of gender, race/ethnicity, and geographic disparities in the United States.Front Nephrol. 2024 Jan 15;3:1339312. doi: 10.3389/fneph.2023.1339312. eCollection 2023. Front Nephrol. 2024. PMID: 38288382 Free PMC article.
-
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.CMAJ. 1993 Sep 1;149(5):575-84. CMAJ. 1993. PMID: 8364814 Free PMC article. Review. No abstract available.
-
Screening and prevention of chronic kidney disease.J Natl Med Assoc. 2002 Aug;94(8 Suppl):55S-62S. J Natl Med Assoc. 2002. PMID: 12152913 Free PMC article.
-
A genome scan for renal function among hypertensives: the HyperGEN study.Am J Hum Genet. 2001 Jan;68(1):136-144. doi: 10.1086/316927. Epub 2000 Dec 12. Am J Hum Genet. 2001. PMID: 11115379 Free PMC article.
-
Do calcium channel blockers have renal protective effects?Drugs Aging. 1994 Oct;5(4):263-87. doi: 10.2165/00002512-199405040-00004. Drugs Aging. 1994. PMID: 7827397 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical